Ocular Therapeutix Inc. Common Stock (OCUL)

About OCUL

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunc…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

325

Website

www.ocutx.com/

Fundamentals

1-day range

$10.34$10.81

Market cap

$1.84B

P/E (trailing)

—

P/E (forward)

-7.13

EPS (trailing)

$-1.41

Dividend yield

—

Beta

0.96

Avg. volume

2.67M

Forecasts

11 analyst ratings

Ocular Therapeutix Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• OCUL

  Ocular Therapeutix Inc. Common Stock

  $10.36

  ▼ 4.25%
  Market cap $1.84BP/E —
  $6.23$16.44
• GENB

  Generate Biomedicines Inc. Common Stock

  $15.33

  ▼ 2.79%
  Market cap $1.84BP/E —
  $11$22.67
• STOK

  Stoke Therapeutics Inc. Common Stock

  $31.61

  ▼ 3.01%
  Market cap $1.84BP/E —
  $18.8$40.22
• URGN

  UroGen Pharma Ltd. Ordinary Shares

  $43.61

  ▼ 4.15%
  Market cap $1.88BP/E —
  $15.86$50.81
• ANIP

  ANI Pharmaceuticals Inc.

  $72.83

  ▼ 0.93%
  Market cap $1.80BP/E 18.72
  $70.15$99.5
• NBTX

  Nanobiotix S.A. American Depositary Shares

  $41.28

  ▼ 8.59%
  Market cap $1.88BP/E —
  $7.02$47.66
• AUPH

  Aurinia Pharmaceuticals Inc Ordinary Shares

  $16.3

  ▼ 1.09%
  Market cap $1.89BP/E 6.39
  $10.34$19.25

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Why Is Ocular Therapeutix Stock Gaining Monday?
  benzinga · 8/17/2026

Institutional Ownership

March 31, 2026

Total shares held

207.47M

Total value held

$1.71B

Institutional holders

264